![TRAIL/Apo2L, Human TRAIL/Apo2L, Human](/product/documents/down?doc_name=Z03124_Activity.jpg&file=scm_files/productFile_notes/2018/04/17/042527814faf3c7c6777ca08dc231d16.jpg)
ED₅₀< 40 ng/mL, measured by the cell growth inhibitory assay using RPMI-8226 cells, corresponding to a specific activity of > 2.5 × 10⁴units/mg.
TRAIL/Apo2L, Human
TRAIL/Apo2L, also known as Tumor Necrosis Factor Super-Family 10 (TNFSF10), is a pleiotropic cytokine thatbelongs to the TNF superfamily. The full length TRAIL expressed in vivo is a Type II transmembrane protein, although the soluble form also exists and functions. TRAIL has four major receptors: two death receptors DR4 and DR5, two decoy receptors DcR1 and DcR2. TRAIL binds to the death receptors, recruits the FAS-associated death domain, activates caspases 8 and 10, and eventually leads to apoptosis. Because of its antitumor potential, TRAIL is actively studied as a therapeutic agent. On the other hand, abnormal expression of TRAIL in small arteries can induce the proliferation of smooth muscle cells, resulting in increasing vascular remodeling and pulmonary arterial hypertension.
|
Z03124 |
|
|
|
|
|
¥300 |
|
|
|
|
联系黄金城集团 |